Page last updated: 2024-10-30

memantine and Long Sleeper Syndrome

memantine has been researched along with Long Sleeper Syndrome in 6 studies

Research Excerpts

ExcerptRelevanceReference
"Memantine was well tolerated in PD; however, specific measures of sleepiness, fatigue, depression, and attention did not significantly improve."5.15Memantine for non-motor features of Parkinson's disease: a double-blind placebo controlled exploratory pilot trial. ( Davidson, A; Lai, D; Ondo, WG; Shinawi, L, 2011)
"Whilst dementia has long been synonymous with AD, it is becoming more widely accepted as part of the clinical spectrum in PD (PDD)."2.53Current Treatment Options for Alzheimer's Disease and Parkinson's Disease Dementia. ( Lewis, SJ; Szeto, JY, 2016)
"Although Parkinson's disease (PD) has been considered to primarily affect motor abilities, increasing emphasis is being placed on cognitive and behavioural impairment in this disorder."2.44Cognitive and behavioural impairment in Parkinson's disease. ( Freedman, M; Merims, D, 2008)
" Three head-to-head trials of ChEIs in the treatment of AD have been published to date, but are limited due to their open-label design, rates of titration, and the drug dosage levels utilised."2.42The benefits and risks associated with cholinesterase inhibitor therapy in Alzheimer's disease. ( Herrmann, N; Lanctôt, KL; Thompson, S, 2004)

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's4 (66.67)29.6817
2010's2 (33.33)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Szeto, JY1
Lewis, SJ1
Merims, D1
Freedman, M1
Brodaty, H1
Ishida, T1
Kamei, C1
Ondo, WG1
Shinawi, L1
Davidson, A1
Lai, D1
Thompson, S1
Lanctôt, KL1
Herrmann, N1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A 16 Week, Investigator-initiated, Single-center, Double Blind, Randomized, Placebo-controlled Trial of Namenda® (Memantine Hcl) for Non-motor Symptoms in Parkinson's Disease[NCT00646204]Phase 440 participants (Actual)Interventional2006-04-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Analyses Will be Computed for the Categorical Dependent Variable (DV): Global Tremor Assessment by Examiner

Change from baseline to end of study in the following assessment: global tremor assessment by examiner. The maximum total score is 48 and would indicate a high prevalence of tremor. The minimum total score is 0 and would indicate no tremor. (NCT00646204)
Timeframe: Baseline and 16 weeks

,
Interventionscores on a scale (Mean)
Baseline16 Weeks
Memantine-12.82.8
Placebo-22.82.8

Unified Parkinson Disease Rating Scale (UPDRS).

Assess the overall change from baseline in ON state motor United Parkinson Disease Rating scale (UPDRS) scores as assessed in the scale. The minimum score is 0 and the maximum score 199. The maximum score of 199 means the worst possible disability from Parkinson's Disease. (NCT00646204)
Timeframe: Baseline and 16 weeks

,
Interventionunits on a scale (Mean)
Before treatmentAfter treatment
Memantine-11210
Placebo-21210

Reviews

3 reviews available for memantine and Long Sleeper Syndrome

ArticleYear
Current Treatment Options for Alzheimer's Disease and Parkinson's Disease Dementia.
    Current neuropharmacology, 2016, Volume: 14, Issue:4

    Topics: Alzheimer Disease; Animals; Antiparkinson Agents; Cholinesterase Inhibitors; Cognitive Behavioral Th

2016
Cognitive and behavioural impairment in Parkinson's disease.
    International review of psychiatry (Abingdon, England), 2008, Volume: 20, Issue:4

    Topics: Antiparkinson Agents; Cognition Disorders; Dementia; Disease Progression; Humans; Incidence; Lewy Bo

2008
The benefits and risks associated with cholinesterase inhibitor therapy in Alzheimer's disease.
    Expert opinion on drug safety, 2004, Volume: 3, Issue:5

    Topics: Aged; Alzheimer Disease; Animals; Basal Ganglia Diseases; Bradycardia; Central Nervous System Diseas

2004

Trials

1 trial available for memantine and Long Sleeper Syndrome

ArticleYear
Memantine for non-motor features of Parkinson's disease: a double-blind placebo controlled exploratory pilot trial.
    Parkinsonism & related disorders, 2011, Volume: 17, Issue:3

    Topics: Aged; Antiparkinson Agents; Depression; Double-Blind Method; Fatigue; Female; Humans; Male; Memantin

2011

Other Studies

2 other studies available for memantine and Long Sleeper Syndrome

ArticleYear
Three steps forward, two steps back in helping people with dementia.
    The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry, 2009, Volume: 17, Issue:2

    Topics: Dementia; Humans; Memantine; Self-Help Devices; Sleep Wake Disorders

2009
Characteristic effects of anti-dementia drugs on rat sleep patterns.
    Journal of pharmacological sciences, 2009, Volume: 109, Issue:3

    Topics: Animals; Dementia; Donepezil; Dose-Response Relationship, Drug; Electroencephalography; Electromyogr

2009
chemdatabank.com